Found: 12
Select item for more details and to access through your institution.
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2412, doi. 10.1111/dom.15560
- By:
- Publication type:
- Article
IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2643, doi. 10.1111/dom.13851
- By:
- Publication type:
- Article
IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2643, doi. 10.1111/dom.13851
- By:
- Publication type:
- Article
Efficacy of iGlarLixi, a fixed‐ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 11, p. 2680, doi. 10.1111/dom.13438
- By:
- Publication type:
- Article
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Triple Therapy in Type 2 Diabetes.
- Published in:
- Diabetes Care, 2006, v. 29, n. 3, p. 554
- By:
- Publication type:
- Article
The TRINITY Study: distribution of systolic blood pressure reductions.
- Published in:
- Integrated Blood Pressure Control, 2013, v. 6, p. 89, doi. 10.2147/IBPC.S45450
- By:
- Publication type:
- Article
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
- Published in:
- Obesity Facts: The European Journal of Obesity, 2020, v. 13, n. 6, p. 572, doi. 10.1159/000511130
- By:
- Publication type:
- Article
1003-P: Clinical Response (HbA<sub>1c</sub> ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA<sub>1c</sub> and Body Weight in the SUSTAIN Program.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1003-P
- By:
- Publication type:
- Article